Other languages Akebia Therapeutics, Inc.

Equities

AKBA

US00972D1054

Market Closed - Nasdaq Other stock markets 16:00:00 2024-06-26 EDT			5-day change	1st Jan Change
0.9247 ^USD	+7.94%		-1.63%	-25.43%

06-24	Akebia Therapeutics Names Erik Ostrowski CFO, CBO	MT
06-24	Akebia Therapeutics, Inc. Appoints Erik Ostrowski as Senior Vice President and Chief Business Officer	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Akebia Therapeutics Names Erik Ostrowski CFO, CBO	06-24
Akebia Therapeutics, Inc. Appoints Erik Ostrowski as Senior Vice President and Chief Business Officer	06-24
Akebia Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09
Akebia Therapeutics, Inc. and STA Pharmaceutical Hong Kong Limited Enters into Second Amendment to the Supply Agreement	04-16
Sector Update: Health Care Stocks Advance Premarket Thursday	03-28
Sector Update: Health Care	03-28
Akebia Therapeutics Shares Jump Pre-Bell on FDA Approval of Anemia Treatment for Chronic Kidney Disease Dialysis Patients	03-28
U.S. FDA approves Akebia's anemia drug	03-27
U.S. FDA approves Akebia's anemia drug	03-27
Akebia Therapeutics, Inc. Receives FDA Approval of Vafseo Tablets for the Treatment of Anemia Due to Chronic Kidney Disease in Adult Patients on Dialysis	03-27
Akebia Therapeutics, Inc. Announces Management Changes, Effective March 22, 2024	03-15
Akebia Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-14
Akebia Therapeutics, Inc. Provides Revenue Guidance for the Year 2024	03-14
Akebia Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-14
Akebia Therapeutics Names Nicholas Grund as Chief Commercial Officer	01-09
Akebia Therapeutics Announces Appointment of Nicholas Grund as Chief Commercial Officer	01-09
Akebia Therapeutics, Inc. Announces the Appointment of Richard C. Malabre as Chief Accounting Officer and Principal Accounting Officer	01-08
Akebia Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-08
Akebia Therapeutics Says FDA Accepts Vadadustat Resubmission	23-10-25
Akebia Therapeutics, Inc. Announces Five Poster Presentations at ASN Kidney Week 2023	23-10-18

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Akebia Therapeutics, Inc.

Equities

AKBA

US00972D1054

Other languages

Filters